Esther Kim
Family Medicine · Las Vegas, NVNPI 1023500352
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,293 and has fallen 73.0% since, to $349 in 2025.
Across 126 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$474
- Corcept Therapeutics$440
- Pfizer$280
- Lucid Diagnostics Inc.$261
- AstraZeneca$211
- Biohaven Pharmaceutical Holding Company Ltd.$178
- plus $952 from 15 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lucid Diagnostics Inc.$500
What the payments were for
- Food & beverage$2,796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $474 |
| Corcept Therapeutics | 15 | $440 |
| Pfizer | 15 | $280 |
| Lucid Diagnostics Inc. | 7 | $261 |
| AstraZeneca(2 entities) | 8 | $211 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $178 |
| Bayer | 5 | $171 |
| Lilly USA, LLC | 10 | $161 |
| Amgen(2 entities) | 8 | $148 |
| Optinose US, Inc. | 5 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Mannkind Corporation | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Novartis | 3 | $48 |
| AbbVie | 3 | $48 |
| Exact Sciences | 3 | $42 |
| Organon | 2 | $30 |
| Boehringer Ingelheim | 1 | $18 |
| Dexcom, Inc. | 1 | $14 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| Scynexis, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$119
- Ozempic$114
- Kerendia$108
How this compares
$2,796 in reported general payments places this provider in the 80th percentile of 902 family medicine providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 30 | $387 |
| Atorvastatin Calcium | 32 | $279 |
| Montelukast Sodium | 13 | $215 |
| Metformin Hcl ErMetformin Hcl | 12 | $208 |
| Lisinopril | 16 | $198 |
| Losartan Potassium | 12 | $150 |
| Alendronate Sodium | 11 | $137 |
| Hydrochlorothiazide | 21 | $132 |
| Donepezil Hcl | 13 | $118 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $108 |
| Pravastatin Sodium | 11 | $85 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Las Vegas
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Warren MagnusLas Vegas$70K
- Kimberly AdamsLas Vegas$51K
- Mandeep GillLas Vegas$24K
- Francis JimenezLas Vegas$20K
- Ryan HuangLas Vegas$18K
- Ma Francesca ChamianLas Vegas$17K
- Leo CapobiancoLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.